Journal of Pharmaceutical and Biopharmaceutical Research

This study documents the stepwise development and evaluation of a generic Lymecycline 408 mg hard gelatin capsule manufactured locally in Pakistan. The formulation process began with the selection of suitable pharmacopeial excipients after conducting accelerated compatibility testing to ensure that no undesirable physical or chemical interactions occurred with the active ingredient. Based on these preliminary investigations, a stable capsule composition was finalized. The finished capsules were evaluated according to British Pharmacopoeia requirements. All tested quality attributes, including assay, dissolution behavior, content uniformity, and moisture content, were found to comply with the specified limits. These results confirmed the consistency and integrity of the developed dosage form. Quantitative analysis of Lymecycline was carried out using a high-performance liquid chromatography method that was validated prior to routine application. During validation, parameters such as specificity, precision under repeat and intermediate conditions, accuracy through recovery assessment, robustness against minor variations, and system suitability were carefully examined. The method demonstrated reliable and reproducible performance in line with internationally accepted regulatory standards. To assess comparative in-vitro performance, dissolution testing was performed using the USP paddle method in media representing gastric and intestinal pH conditions (pH 1.2, 4.5, and 6.8). In all cases, more than 85% of the drug was released within one hour. Statistical comparison with the reference product, Tetralysal® 300 mg, showed acceptable similarity and difference factor values, indicating comparable release profiles. Overall, the data support that the developed formulation performs equivalently to the reference product and may be considered suitable for local production and further regulatory processing.